A rising tide lifts all boats, but AngioDynamics (NASDAQ:ANGO) seems to be stuck in shallow waters. The company's recent financials paint a challenging picture, with a net income of -$34 million and a profit margin of -12%. Revenue stands at $293 million, yet its high forward P/E of around 96 suggests the market is pricing in significant growth potential that hasn't materialized yet. The enterprise value to revenue ratio of about 1.36 and a market cap of roughly $455 million highlight a company still in the early stages of recovery or transformation. With a relatively high short ratio of 8.62X and a probability of bankruptcy at over 37%, investors should approach with caution. While the stock's target price of $18.25 offers some optimism, the current valuation indicates considerable risk, especially given the ongoing losses and modest cash per share. For those considering a position, it’s essential to weigh the potential for future growth against the hurdles that lie ahead. With renewed interest in the healthcare equipment sector, it’s a good time to take a closer look at AngioDynamics. As we approach November, it’s worth asking whether the stock is fairly valued and if that valuation can hold up. I’ll share some insights on AngioDynamics’ current price levels and what they might mean for investors considering a position. Understanding whether the stock’s valuation is justified can help you make more informed decisions about its potential risks and rewards.
We determine the current worth of AngioDynamics using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of AngioDynamics based exclusively on its
fundamental and basic
technical indicators. By analyzing AngioDynamics's
financials, quarterly and monthly indicators, and related drivers such as
dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of AngioDynamics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of AngioDynamics. We calculate exposure to AngioDynamics's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to AngioDynamics's related companies.
AngioDynamics Investment Alerts
AngioDynamics investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring AngioDynamics performance across your portfolios.Please check all
investment alerts for AngioDynamics
AngioDynamics Valuation Ratios as Compared to Competition
Our valuation model uses many indicators to compare AngioDynamics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AngioDynamics competition to find
correlations between indicators driving the intrinsic value of AngioDynamics.
AngioDynamics Gross Profit
AngioDynamics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing AngioDynamics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show AngioDynamics Gross Profit growth over the last 10 years. Please check AngioDynamics'
gross profit and other
fundamental indicators for more details.
What is driving AngioDynamics Investor Appetite?
The recent roll up in AngioDynamics short term price appreciation could raise concerns from investors as the firm is trading at a share price of
11.07 on
1,281,230 in volume. The company directors and management have successfully maneuvered the firm at convenient times to take advantage of all market conditions in
September. The stock standard deviation of daily returns for 90 days investing horizon is currently 2.35. The current volatility is consistent with the ongoing market swings in
September 2025 as well as with AngioDynamics unsystematic, company-specific events.
| 2022 | 2023 | 2024 | 2025 (projected) |
Gross Profit | 174.2M | 154.7M | 147.4M | 132.5M | Total Revenue | 338.8M | 303.9M | 292.5M | 249.7M |
Margins Breakdown
AngioDynamics profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or AngioDynamics itself as indicators of financial health and management effectiveness.
Please look more closely at the different varieties of AngioDynamics profit margins.
| Pretax Profit Margin | (0.11) |
| Operating Profit Margin | (0.0782) |
| Net Profit Margin | (0.11) |
| Gross Profit Margin | 0.59 |
AngioDynamics Market Cap is decreasing over the last 8 years. Also, AngioDynamics Days Sales Outstanding is very stable at the moment. As Warren Buffett once said, price is what you pay, value is what you get. AngioDynamics (NASDAQ:ANGO) currently trades at a Price to Book ratio of 2.40X, with a target price of 18.25 suggesting a potential upside of around 4. However, the stock faces headwinds with a negative operating margin of -0.05 and a net income loss of 34 million, reflecting ongoing profitability challenges. Despite a modest revenue growth of 12.9%, the company's risk profile shows a probability of bankruptcy at 37.36% and a beta of 0.64, indicating lower market volatility but still notable risk. With a current valuation of approximately 399 million and a debt-to-equity ratio of just 0.14%, AngioDynamics might be undervalued if it can turn around its operating performance, but investors should weigh the significant downside risks before expecting a surge in November 2025..
AngioDynamics is projected to stay under $11.29 in November
With downside deviation dropping to 2.75, AngioDynamics appears to be entering a calmer phase, hinting at less price fluctuation ahead. This could mean more stable trading, especially with expectations that it will stay below $11.29 in November. For investors, this signals a potentially lower risk environment, making it easier to hold or consider new positions without fearing sudden drops. As of October 2nd, the stock’s risk-adjusted performance stands at 0.0564, with a mean deviation of 1.75. Using technical analysis, traders can analyze historical prices and volume trends to identify patterns that may hint at the company’s future price movements.
Overall, these indicators suggest a quieter period, which might appeal to those seeking more predictability in their investments.Given the recent decline in AngioDynamics' stock, investors should approach with caution. The current valuation suggests a possible downside price of around
8.61, which indicates some downside risk if the company doesn't meet expectations. While the analyst consensus remains a strong buy, the estimated target price of approximately
18.25 offers a potential upside of about
13.31, but this is still below the highest analyst estimate of
20.26. With only a handful of strong buy ratings and a valuation market value of roughly
11.07, it’s important to weigh whether the recent dip presents a buying opportunity or signals underlying issues. As always, consider your risk tolerance and look for confirmation before making any moves..
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetEditorial Staff
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of AngioDynamics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com